RadNet (RDNT) Stock Price, News & Analysis

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RDNT shares.
View RDNT analyst ratings or view top-rated stocks.

3 analysts have issued 1-year price targets for RadNet's shares. Their RDNT share price targets range from $30.00 to $42.00. On average, they predict the company's stock price to reach $34.00 in the next twelve months. This suggests that the stock has a possible downside of 5.2%.
View analysts price targets for RDNT or view top-rated stocks among Wall Street analysts.

RadNet's stock was trading at $18.83 at the start of the year. Since then, RDNT shares have increased by 90.5% and is now trading at $35.87.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our RDNT earnings forecast.

RadNet, Inc. (NASDAQ:RDNT) released its earnings results on Wednesday, November, 8th. The medical research company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.08. The medical research company had revenue of $401.97 million for the quarter, compared to analysts' expectations of $391.63 million. RadNet had a net margin of 0.25% and a trailing twelve-month return on equity of 4.16%. The firm's revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.09 earnings per share.

ETFs with the largest weight of RadNet (NASDAQ:RDNT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Services ETF (XHS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and First Trust Small Cap Growth AlphaDEX Fund (FYC).iShares U.S. Healthcare Providers ETF (IHF).

RadNet updated its FY 2023 earnings guidance on Wednesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.57 billion-$1.61 billion, compared to the consensus revenue estimate of $1.60 billion.

174 employees have rated RadNet Chief Executive Officer Howard G. Berger on Glassdoor.com. Howard G. Berger has an approval rating of 45% among the company's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

RadNet's stock is owned by a number of institutional and retail investors. Top institutional investors include Invesco Ltd. (2.17%), Principal Financial Group Inc. (1.71%), Punch & Associates Investment Management Inc. (1.54%), American Century Companies Inc. (1.10%), Loomis Sayles & Co. L P (0.97%) and Northern Trust Corp (0.95%). Insiders that own company stock include Christine Nayoma Gordon, David L Swartz, John V Crues, Lawrence L Levitt, Lawrence L Levitt, Michael N Murdock, Norman R Hames and Ruth Louisa Villigerwilson.
View institutional ownership trends.

Shares of RDNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.